ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RNAZ vs LITS // OPERATING MARGIN

TransCode Therapeutics Inc. (NASDAQ) VS. Lite Strategy Inc. (NASDAQ) • 15-METRIC TALLY: RNAZ 2 — LITS 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNAZ VS. LITS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RNAZ LITS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -18.90% -16.10 LITS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 11.68 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 RNAZ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.2 35.9 +6.30 RNAZ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $27.6M $29.4M -$1.8M LITS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RNAZ REV LITS REV RNAZ GROSS % LITS GROSS % RNAZ FCF LITS FCF
FY 2025 $78.3M $48.9M — — -$19.5M -$20.8M
FY 2024 $43.8M $65.3M — — -$13.4M -$50.5M
FY 2023 $54.4M $48.8M — — -$18.1M -$52.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNAZ // BETA —
LITS // BETA —